ReShape Lifesciences Inc. - FORM 8-K - EX-99.1 - EXHIBIT 99.1 - February 27, 2020

Attached files

file filename
8-K - 8-K - ReShape Lifesciences Inc.obalon-201910xkearningsrel.htm


Obalon Announces Fourth Quarter and Full Year 2019 Financial Results
SAN DIEGO, CA February 27, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2019.

“2019 was an eventful year for Obalon as we recapitalized and repositioned the business to efficiently leverage our FDA-approved weight loss system through our new retail treatment center business model,” said Bill Plovanic, President and Chief Executive Officer. “We are very pleased with the opening and initial operations of our first treatment center in San Diego California, in addition to the recent opening of our second treatment center in Orange County, California. Our priorities in 2020 are focused on expanding our retail treatment center footprint, raising awareness of the Obalon Centers for Weight Loss™ brand, and working to create shareholder value by building a standardized, repeatable business using the Company-owned or managed retail treatment center model.”

Key Accomplishments in 2019:
•
Opened the first Obalon-managed retail treatment center in San Diego
•
Commercialized Obalon Navigation System and Obalon Touch Inflation Dispenser
•
Streamlined operations and spend to support new commercial strategy
•
Repaid all outstanding long-term debt
•
Promoted Bill Plovanic from Chief Financial Officer to President and Chief Executive Officer
•
Appointed Bob MacDonald as Chief Retail Officer to establish and grow our network of Obalon Centers for Weight Loss facilities
•
Promoted Nooshin Hussainy from Vice President of Finance to Chief Financial Officer
•
Engaged Helmuth T. Billy, MD as Medical Director for Company-managed California retail treatment centers
•
Entered into one-year distribution agreement with distributor for Qatar
•
Announced clinical data presentation at ASMBS annual meeting at Obesity Week 2019 demonstrating clinically meaningful weight loss for patients treated with the Obalon Balloon System with no serious adverse events reported

Fourth Quarter 2019 Results:
The Company reported revenue of $0.8 million for the fourth quarter of 2019, compared to $2.0 million for the fourth quarter of 2018. U.S. revenue of $0.5 million represented 62% of revenue as compared to $0.8 million and 41% of revenue in the fourth quarter of 2018. International revenue

1


of $0.3 million represented 38% of revenue in the fourth quarter of 2019, compared to $1.2 million and 59% of revenue in the fourth quarter of 2018.

Cost of revenue was $0.6 million during the three months ended December 31, 2019, down from $1.5 million for the prior-year comparable period. Gross profit for the fourth quarter of 2019 was $0.2 million, resulting in a gross margin of 20%, compared to a gross profit of $0.5 million and gross margin of 26% for the fourth quarter of 2018.

Research and development expense for the fourth quarter of 2019 totaled $1.5 million, down from $2.3 million in the fourth quarter of 2018. Selling, general and administrative expense decreased to $3.6 million for the fourth quarter of 2019, compared to $6.9 million in the fourth quarter of 2018.

Operating loss for the fourth quarter of 2019 was $5.0 million, compared to an operating loss of $8.7 million for the fourth quarter of 2018.

Net loss in the fourth quarter of 2019 was $4.9 million, compared to a net loss of $8.8 million in the fourth quarter of 2018. The net loss per share was $0.64 for the fourth quarter of 2019 as compared to the net loss per share of $3.87 for the fourth quarter of 2018.

As of December 31, 2019, Obalon had cash and cash equivalents of $14.1 million and no outstanding debt.

Full Year 2019 Results:
Obalon reported full year 2019 revenue of $3.3 million, as compared to $9.1 million for the full year 2018. U.S. revenue of $2.4 million represented 73% of full year 2019 revenue, decreasing from $4.7 million or 52% of full year 2018 revenue. International revenue of $0.9 million in 2019 equated to 27% of full year 2019 revenue as compared to $4.4 million of international revenue in 2018 which equated to 48% of full year 2018 revenue.

Gross profit for the full year 2019 was $0.3 million, resulting in a gross margin of 10%, as compared to $3.7 million for the full year 2018 and a gross margin of 40%.

Research and development expense totaled $6.9 million for the full year 2019, as compared to $10.7 million for the full year 2018. Selling, general and administrative expense decreased to $16.7 million for the full year 2019, as compared to $29.9 million for the full year 2018.


2


Operating loss for the full year 2019 was $23.2 million, compared to an operating loss of $37.0 million for the full year 2018.

Net loss was reported at $23.7 million for the full year 2019 compared to a net loss of $37.4 million for the full year 2018. The net loss per share was $5.03 for the full year 2019, as compared to the net loss per share of $19.64 for the full year 2018.

Call Information
A conference call to discuss fourth quarter and full year 2019 financial results is scheduled for today, February 27, 2020, at 8:30 AM Eastern Time (5:30 AM Pacific Time). Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 6573298.  Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event.  The conference call will also be webcast live at:  https://edge.media-server.com/mmc/p/c8zmkz5x. An archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics, Inc. website located at http://investor.obalon.com in the “News & Events” section. 

Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Obalon’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to new products and their potential benefits. All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Obalon, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward looking statements. The risks and uncertainties that may cause actual results to differ materially from Obalon’s current expectations are more fully described in Obalon’s annual report on Form 10-K for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on February 27, 2020, and its other reports, each as filed with the Securities and Exchange Commission. Except as required by law, Obalon assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.

About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit www.obalon.com.


3


For Obalon Therapeutics, Inc.
Investor Contact:
William Plovanic
President & Chief Executive Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
wplovanic@obalon.com






4




OBALON THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except shares and per share data)
 
Three Months Ended December 31,
 
Year Ended December 31,
 
2019
 
2018
 
2019
 
2018
 
(Unaudited)
 
 
 
 
Revenue
$
787

 
$
2,036

 
$
3,281

 
$
9,101

Cost of revenue
627

 
1,504

 
2,950

 
5,423

Gross profit
160

 
532

 
331

 
3,678

Operating expenses:
 
 
 

 
 
 
 
Research and development
1,492

 
2,338

 
6,893

 
10,697

Selling, general and administrative
3,643

 
6,854

 
16,668

 
29,946

Total operating expenses
5,135

 
9,192

 
23,561

 
40,643

Loss from operations
(4,975
)
 
(8,660
)
 
(23,230
)
 
(36,965
)
Interest income (expense), net
63

 
(62
)
 
(385
)
 
(226
)
Other expense
(1
)
 
(34
)
 
(61
)
 
(189
)
      Net loss
(4,913
)
 
(8,756
)
 
(23,676
)
 
(37,380
)
Other comprehensive income
—

 
2

 
—

 
5

Net loss and comprehensive loss
$
(4,913
)
 
$
(8,754
)
 
$
(23,676
)
 
$
(37,375
)
Net loss per share, basic and diluted
$
(0.64
)
 
$
(3.87
)
 
$
(5.03
)
 
$
(19.64
)
Weighted-average common shares outstanding, basic and diluted
7,692,673

 
2,259,645

 
4,706,775

 
1,903,734



5




OBALON THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except shares and par value data)
 
December 31,
 
2019
 
2018
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
14,055

 
$
21,187

Short-term investments
—

 
2,548

Accounts receivable, net
285

 
870

Inventory
1,936

 
1,580

Other current assets
1,959

 
2,462

Total current assets   
18,235

 
28,647

Lease right-of-use assets
1,077

 
—

Property and equipment, net
1,081

 
1,739

Total assets   
$
20,393

 
$
30,386

Liabilities and Stockholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
648

 
$
1,159

Accrued compensation
820

 
3,805

Deferred revenue
424

 
352

Other current liabilities
1,524

 
1,985

Current portion of lease liabilities
561

 
—

Current portion of long-term loan
—

 
9,930

Total current liabilities   
3,977

 
17,231

Lease liabilities long term
567

 
—

Other long-term liabilities
—

 
48

Total liabilities   
4,544

 
17,279

 
 
 
 
Commitments and contingencies
 
 
 
 
 
 
 
Stockholders’ equity:
 
 
 
Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2019 and December 31, 2018; 7,724,100 and 2,351,333 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively
8

 
2

Additional paid-in capital
188,271

 
161,859

Accumulated deficit
(172,430
)
 
(148,754
)
Total stockholders’ equity
15,849

 
13,107

Total liabilities and stockholders’ equity
$
20,393

 
$
30,386











6


OBALON THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
 
Year Ended December 31,
 
2019
 
2018
 
 
Operating activities:
 

 
 

Net loss
$
(23,676
)
 
$
(37,380
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation
479

 
581

Stock-based compensation
2,983

 
4,693

Amortization of right-of-use asset
415

 
—

Loss on disposal of fixed assets
128

 
107

Accretion of investment discount, net
(2
)
 
(50
)
Amortization of debt discount
70

 
37

Change in operating assets and liabilities:
 
 
 
Accounts receivable, net
585

 
3,353

Inventory
12

 
(162
)
Other current assets
411

 
98

Accounts payable
(543
)
 
70

Accrued compensation
(2,985
)
 
(689
)
Deferred revenue
72

 
(158
)
Lease liabilities, net
(364
)
 
—

Other current and long term liabilities
(451
)
 
68

Net cash used in operating activities
(22,866
)
 
(29,432
)
Investing activities:
 

 
 

Purchases of short-term investments
—

 
(9,102
)
Maturities of short-term investments
2,550

 
29,901

Purchases of property and equipment
(194
)
 
(1,282
)
Net cash provided by investing activities
2,356

 
19,517

Financing activities:
 

 
 

Proceeds from issuance of common stock and warrants, net of issuance costs
23,377

 
9,823

Proceeds from long-term loan, net of issuance costs
10,000

 
—

Fees paid in connection with loan amendment
—

 
(30
)
Repayments of long-term loans
(20,000
)
 
—

Proceeds from common stock issued under employee stock purchase plan
—

 
148

Proceeds from sale of common stock upon exercise of stock options
1

 
53

Net cash provided by financing activities
13,378

 
9,994

Net (decrease) increase in cash and cash equivalents
(7,132
)
 
79

Cash and cash equivalents at beginning of period
21,187

 
21,108

Cash and cash equivalents at end of period
$
14,055

 
$
21,187

Supplemental cash flow information:
 

 
 

Interest paid
$
719

 
$
642

Income taxes paid
$
—

 
$
7

Property and equipment in accounts payable
$
32

 
$
201

Unpaid issuance costs
$
—

 
$
250

Fair value of commitment shares issued
$
—

 
$
595


7

ReShape Lifesciences Inc. Reports